BACKGROUND: Transplant recipients are at risk of posttransplant lymphoproliferative disease (PTLD). METHODS: Thirty-six pediatric transplant recipients were evaluated (18 hematopoietic stem cell and 18 liver recipients; 12 had PTLD). We studied 207 longitudinal plasma samples from these recipients for three markers of B-cell activation or clonality: immunoglobulin free light chains (FLCs), soluble CD30 (sCD30), and monoclonal immunoglobulins (M-proteins). RESULTS: Kappa FLCs, lambda FLCs, and sCD30 were elevated in 20.8%, 28.0%, and 94.2% of plasma specimens, respectively. Free light chain and sCD30 levels increased significantly 1.18 to 1.82 fold per log10 Epstein-Barr virus (EBV) load in peripheral blood. Five PTLD cases manifested elevated FLCs with an abnormal kappa/lambda ratio, suggesting monoclonal FLC production. M-proteins were present in 91% of PTLD cases versus 50% to 67% of other recipients with high or low EBV loads (P=0.13). Concordance of FLCs, M-proteins, and PTLD tumor light chain restriction was imperfect. For example, one PTLD case with an IgG lambda M-protein had a tumor that was kappa restricted, and another case with an M-protein had a T-cell PTLD. In an additional case, an IgM kappa M-protein and excess kappa FLCs were both detected in plasma at PTLD diagnosis; although the tumor was not restricted at diagnosis, kappa restriction was present 5 years later when the PTLD relapsed. CONCLUSIONS: Plasma markers of B-cell dysfunction are frequent after transplantation and associated with poor EBV control. These abnormal markers may be produced by oligoclonal B-cell populations or PTLD tumor cells and could potentially help identify recipients at high risk of PTLD.
BACKGROUND: Transplant recipients are at risk of posttransplant lymphoproliferative disease (PTLD). METHODS: Thirty-six pediatric transplant recipients were evaluated (18 hematopoietic stem cell and 18 liver recipients; 12 had PTLD). We studied 207 longitudinal plasma samples from these recipients for three markers of B-cell activation or clonality: immunoglobulin free light chains (FLCs), soluble CD30 (sCD30), and monoclonal immunoglobulins (M-proteins). RESULTS: Kappa FLCs, lambda FLCs, and sCD30 were elevated in 20.8%, 28.0%, and 94.2% of plasma specimens, respectively. Free light chain and sCD30 levels increased significantly 1.18 to 1.82 fold per log10 Epstein-Barr virus (EBV) load in peripheral blood. Five PTLD cases manifested elevated FLCs with an abnormal kappa/lambda ratio, suggesting monoclonal FLC production. M-proteins were present in 91% of PTLD cases versus 50% to 67% of other recipients with high or low EBV loads (P=0.13). Concordance of FLCs, M-proteins, and PTLD tumor light chain restriction was imperfect. For example, one PTLD case with an IgG lambda M-protein had a tumor that was kappa restricted, and another case with an M-protein had a T-cell PTLD. In an additional case, an IgM kappa M-protein and excess kappa FLCs were both detected in plasma at PTLD diagnosis; although the tumor was not restricted at diagnosis, kappa restriction was present 5 years later when the PTLD relapsed. CONCLUSIONS: Plasma markers of B-cell dysfunction are frequent after transplantation and associated with poor EBV control. These abnormal markers may be produced by oligoclonal B-cell populations or PTLD tumor cells and could potentially help identify recipients at high risk of PTLD.
Authors: L Ahdieh; S J Gange; R Greenblatt; H Minkoff; K Anastos; M Young; M Nowicki; A Kovacs; M Cohen; A Muñoz Journal: Am J Epidemiol Date: 2000-11-15 Impact factor: 4.897
Authors: Joanne M Wroblewski; Angela Copple; Lydia P Batson; Cheri D Landers; John R Yannelli Journal: J Immunol Methods Date: 2002-06-01 Impact factor: 2.303
Authors: Matthew J Maurer; James R Cerhan; Jerry A Katzmann; Brian K Link; Cristine Allmer; Clive S Zent; Timothy G Call; Kari G Rabe; Curtis A Hanson; Neil E Kay; Susan L Slager; Thomas E Witzig; Tait D Shanafelt Journal: Blood Date: 2011-07-15 Impact factor: 22.113
Authors: B Savoldo; J Goss; Z Liu; M H Huls; S Doster; A P Gee; M K Brenner; H E Heslop; C M Rooney Journal: Transplantation Date: 2001-09-27 Impact factor: 4.939
Authors: Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton Journal: N Engl J Med Date: 2002-02-21 Impact factor: 91.245
Authors: Eric A Engels; Linda W Jennings; Matthew J Everly; Ola Landgren; Kazunori Murata; Elizabeth L Yanik; Ruth M Pfeiffer; Nicholas Onaca; Goran B Klintmalm Journal: Transplant Direct Date: 2018-05-15
Authors: Eric A Engels; Christina A Clarke; Ruth M Pfeiffer; Charles F Lynch; Dennis D Weisenburger; Todd M Gibson; Ola Landgren; Lindsay M Morton Journal: Am J Transplant Date: 2013-05-01 Impact factor: 9.369